7:45 am Coffee Room Opens

8:30 am Chair’s Opening Remarks

Unpublished Clinical Data Drop

8:45 am Describing the Rationale Behind Innate Cell Engager and Cell Therapy Combination Studies, and Sharing Early Clinical Outcomes in Hodgkin Lymphoma

Synopsis

  • Outlining the innate and adaptive immune mechanisms to recognize and kill tumor cells, and the avenues for synergistic stimulation (crosstalk)
  • Describing the preclinical data which substantiates synergy between innate cell engager and immune cell functions to enhance in vivo mechanism of action
  • Comparing and contrasting the mode of action and early clinical evidence of AFM13 with NK cell therapies vs. checkpoint inhibitor and in monotherapy, and where promise lies to elicit maximum clinical benefit

9:15 am Examining Data from NK Cell Therapy to Assess Therapeutic Efficacy, and Preclinical Findings from CAR-NK Cells

Synopsis

  • Discussing if results indicate the potential for NK cell therapy to prolong event-free survival in patients, and the implications for treatment regimens
  • Considering the requirement for multiple infusions based on preliminary clinical results
  • Examining unpublished preclinical data from CAR-NK constructs

9:45 am Pharma Leaders Fireside Chat: A View of the Innate Immune System as an ‘Off-the-Shelf’ Approach to Cell Therapy

Synopsis

  • Highlighting the synergies between autologous and allogeneic cell therapies to create a common chassis for development which can ‘plug and play’ with big pharma infrastructure
  • Sharing thoughts on how the intrinsic service component in the commercialization of autologous and allogeneic therapies requires similar patient preparation, additional treatment, follow up, and specialized workforce and how these fit into the ‘big pharma’ model
  • Identifying opportunities for shared synergy across different pipelines, creating an outline to develop pipelines with a common thread across the industry to facilitate collaborations, mergers, and acquisitions

10:30 am Morning Refreshments & Tech Slam

11:00 am

12:30 pm Lunch & Networking

1:30 pm

3:15 pm Afternoon Poster Session & Networking

4:00 pm Tracking Cells In Vivo and Engineering Cells to Drive Tumor-Specific Homing

Synopsis

  • Discussing the importance of understanding where cells go, which cell subsets they interact directly with, and how this can inform therapeutic design
  • Sharing strategies to label and track engineered cell therapies with MRI and PET scans in vivo to investigate where cells accumulate, the proportion of the dose that is exposed to the tumor, and to monitor in vivo persistence
  • Providing an overview of strategies to enhance homing to tumor tissues such as chemokine expression, chemokine receptor knock outs, how these approaches function in vivo, and the relative challenges of these approaches

4:30 pm Developing Engineering approaches to Harness NK cell Biology in Concert with Adaptive Immune Cells to Orchestrate a Concerted Anti-Tumor Response

Synopsis

  • Discussing how to use the biology of NK cell innate immune biology and ‘lure’ in the adaptive immune system to affect a comprehensive anti-tumor response
  • Leveraging a pseudo-engineering method to manipulate NK cells with TGF-b treatment during expansion to elicit diverse effects to engage the adaptive immune system
  • Designing NK cell-specific CAR constructs to harness innate immune signaling cascades whilst maintaining CAR recognition and potency

5:00 pm Losing Lymphodepletion for Innate Immune Cell Therapies: Discussing the Rationale for Current Preconditioning Paradigms, Caveats for NK Cells, and Outcomes with Innate Immune-Tailored Treatment Regimens

Synopsis

  • Discussing the optimal PK profile of NK cells, the requirements for expansion vs. T cells, and how to dose accordingly to maximize persistence
  • Accounting for natural cytokine production by NK cells to induce a broad anti-tumor response
  • Controlling the immunosuppressive TME with a combination of IL-15 and atezolizumab without the need to modulate Treg, which are not primary suppressive factors for NK cells

5:30 pm Chair’s Closing Remarks

5:45 pm End of Conference